SCHEMBL647520

SCHEMBL647520

CCCCn1c(-c2ccccc2)nc(-c2cccc(OCC)c2)c1CN(Cc1ccc(OC(F)F)cc1)Cc1ccc2c(c1)OCO2

nearest known ligand 0.54

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
C5AR1 P21730 1/20 0.54
PPARG P37231 2/20 0.39
PPARA Q07869 2/20 0.39
SMN1; SMN2 Q16637 2/20 0.36
LMNA P02545 1/20 0.36
L3MBTL1 Q9Y468 1/20 0.36
TP53 P04637 2/20 0.36
POLB P06746 2/20 0.36
GAA P10253 1/20 0.36
MAPT P10636 1/20 0.36
PTPN1 P18031 1/20 0.35
GNRHR P30968 2/20 0.35
PPARD Q03181 1/20 0.35
ALDH1A1 P00352 1/20 0.34
TSHR P16473 1/20 0.34
HSP90AA1 P07900 1/20 0.34
HSP90AB1 P08238 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL650543 0.94 C5AR1 (0.57) C5AR1PPARGPPARASMN1; SMN2LMNA
SCHEMBL652021 0.94 C5AR1 (0.54) C5AR1PPARGPPARASMN1; SMN2LMNA
SCHEMBL1912946 0.93 C5AR1 (0.62) C5AR1PPARGPPARASMN1; SMN2LMNA
SCHEMBL651150 0.93 C5AR1 (0.61) C5AR1PPARGPPARASMN1; SMN2LMNA
SCHEMBL648489 0.92 C5AR1 (0.56) C5AR1PPARGPPARASMN1; SMN2LMNA
SCHEMBL652169 0.92 C5AR1 (0.55) C5AR1PPARGPPARASMN1; SMN2LMNA
SCHEMBL649243 0.91 C5AR1 (0.60) C5AR1PPARGPPARASMN1; SMN2LMNA
SCHEMBL651651 0.91 C5AR1 (0.39) C5AR1MAPTALDH1A1TSHR
SCHEMBL650026 0.91 C5AR1 (0.54) C5AR1PPARGPPARASMN1; SMN2LMNA
SCHEMBL649822 0.91 C5AR1 (0.39) C5AR1PPARGPPARAMAPTALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8119665-B2 Aryl imidazoles and related compounds as C5a receptor modulators NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) 2012-02-21 US disclosed
US-8119665-B2 Aryl imidazoles and related compounds as C5a receptor modulators NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) 2012-02-21 US disclosed
US-8119665-B2 Aryl imidazoles and related compounds as C5a receptor modulators NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) 2012-02-21 US disclosed
EP-1490044-A4 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORP (US) 2008-04-16 EP disclosed
US-7186734-B2 Aryl imidazoles and related compounds as C5a receptor modulators NEUROGEN CORPORATION (US) 2007-03-06 US disclosed
US-7186734-B2 Aryl imidazoles and related compounds as C5a receptor modulators NEUROGEN CORPORATION (US) 2007-03-06 US disclosed
US-7186734-B2 Aryl imidazoles and related compounds as C5a receptor modulators NEUROGEN CORPORATION (US) 2007-03-06 US disclosed
EP-1490044-A1 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORPORATION (US) 2004-12-29 EP disclosed
WO-2003084524-A1 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORPORATION (US) 2003-10-16 WO disclosed